Arix Shepherds Atox $30m Funding Amid High Hopes For Start-up's Lead Asset
Executive Summary
Its investment in Atox Bio's $30m Series F financing round added the 12th company to Arix's portfolio, hitting a target set at its February IPO. Atox’s late-stage peptide is designed to modulate a patient’s response to severe infections.
You may also be interested in...
Arix And China's Fosun Ink A Strategic Partnership
A new strategic partnership has been forged between Arix Bioscience and China's Fosun International to develop new business opportunities in China.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.